Markers of tumor-initiating cells predict chemoresistance in breast cancer

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Gong, Chang ^a   Yao, Herui ^a   Liu, Qiang ^a,b   Chen, Jingqi ^a   Shi, Junwei ^a   Su, Fengxi ^a   Song, Erwei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BREAST CANCER RESISTANCE PROTEIN; CYCLINE; DOXORUBICIN; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN 1; SALINOMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD24 ANTIGEN; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; ISOENZYME; RETINAL DEHYDROGENASE;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN EXPRESSION; UPREGULATION; ADULT; BREAST TUMOR; DRUG RESISTANCE; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADULT; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MIDDLE AGED; PHENOTYPE; RETINAL DEHYDROGENASE;

EID: 78650859954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015630     Document Type: Article

References (28)

1. Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-2.
2. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, et al. (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122: 927-39.
3. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H (2005) A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 24: 1403-11.
4. Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, et al. (2006) Int J Cancer 119: 2784-94.
5. Senderowicz AM (2003) Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 52 Suppl 1: S61-73.
6. Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58: 267-84.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-8.
8. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-11.
9. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-67.
10. Al-Hajj M (2007) Cancer stem cells and oncology therapeutics. Curr Opin Oncol 19: 61-4.
11. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123.
12. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(2/low)/ CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-85.
13. Shi W, Harris AL (2006) Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 11: 41-52.
14. Diehn M, Clarke MF (2006) Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98: 1755-7.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-16.
16. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-9.
17. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-59.
18. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-15.
19. Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-30.
20. Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8: 411-24.
21. Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45: 872-7.
22. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, et al. (2007) Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 99: 616-27.
23. Yin L, Castagnino P, Assoian RK (2008) ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res 68: 800-7.
24. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, et al. (2008) Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68: 7905-14.
25. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS (2003) Stem cells in normal breast development and breast cancer. Cell Prolif 36 Suppl 1: 59-72.
26. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, et al. (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65: 6207-19.
27. Nardinocchi L, Puca R, Sacchi A, D'Orazi G (2009) Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitiza-tion of chemoresistant cells to undergo apoptosis. Mol Cancer 8: 1.
28. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, et al. (2001) Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142: 2776-88.